Report Categories
View AllRecent Articles
View All
Is First FRMEP stock showing technical strength First posts 89 EPS beat outperforming analyst estimates
STOK Stoke Therapeutics posts wider than expected Q4 2025 loss shares gain slightly despite steep earnings miss
Pyxis Oncology PYXS Management Strategy Pyxis Oncology posts 156 EPS beat no revenue
EUDA EUDA management outlines new digital health expansion priorities alongside latest quarterly earnings